Stay updated with breaking news from Markus Puhlmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy using a novel 64/67Cu and 203/212Pb double...
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann purchased 60,419 shares of the company’s stock in a transaction on Monday, December 18th. The stock was acquired at an average price of 0.26 per share, for a total transaction of 15,708.94. Following the completion of the transaction, the insider now owns 695,425 shares […]
SEATTLE, Nov. 16, 2023 -- Perspective Therapeutics, Inc. , today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or...
SEATTLE, Oct. 16, 2023 -- Perspective Therapeutics, Inc. , today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 , its...
SEATTLE, Oct. 10, 2023 -- Perspective Therapeutics, Inc. , today announced that two upcoming investigator-initiated trials were presented at the North American Neuroendocrine Tumor Society ...